Cover Image
市場調查報告書

甲狀腺機能低下症:開發中產品分析

Hypothyroidism - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 360910
出版日期 內容資訊 英文 30 Pages
訂單完成後即時交付
價格
Back to Top
甲狀腺機能低下症:開發中產品分析 Hypothyroidism - Pipeline Review, H2 2017
出版日期: 2017年11月14日 內容資訊: 英文 30 Pages
簡介

甲狀腺功能低下是指甲狀腺無法產生足夠的某些重要荷爾蒙病症。症候包括疲勞,便秘,皮膚乾燥,臉部浮腫,肌肉無力,肌肉酸痛,壓痛和僵硬,疼痛和僵硬等。危險因素包括自身免疫性疾病,甲狀腺手術,放射治療和甲狀腺疾病家族病史。

本報告提供甲狀腺機能低下症的治療藥開發情形相關調查分析,提供開發中產品概要,參與治療藥開發的主要企業及藥物簡介,最新的開發平台趨勢等資訊。

簡介

  • 調查範圍

甲狀腺機能低下症概要

治療藥的開發

  • 開發中產品概要
  • 各企業的開發平台
  • 企業開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Genexine Inc
  • Synthonics Inc
  • Titan Pharmaceuticals Inc

藥物簡介

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9878IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypothyroidism - Pipeline Review, H2 2017, provides an overview of the Hypothyroidism (Hormonal Disorders) pipeline landscape.

Hypothyroidism (underactive thyroid) is a condition in which thyroid gland doesn't produce enough of certain important hormones. Signs and symptom include fatigue, constipation, dry skin, puffy face, muscle weakness, muscle aches, tenderness and stiffness, pain and stiffness. Risk factors include autoimmune diseases, thyroid surgery, radiation therapy and family history of thyroid disease.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypothyroidism - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hypothyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypothyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypothyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, IND/CTA Filed and Preclinical stages are 1, 1 and 5 respectively.

Hypothyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypothyroidism (Hormonal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hypothyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypothyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypothyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypothyroidism (Hormonal Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypothyroidism (Hormonal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypothyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 3
  • List of Figures 3
  • Introduction 4
  • Global Markets Direct Report Coverage 4
  • Hypothyroidism - Overview 5
  • Hypothyroidism - Therapeutics Development 6
  • Pipeline Overview 6
  • Pipeline by Companies 7
  • Products under Development by Companies 8
  • Hypothyroidism - Therapeutics Assessment 9
  • Assessment by Target 9
  • Assessment by Mechanism of Action 11
  • Assessment by Route of Administration 13
  • Assessment by Molecule Type 15
  • Hypothyroidism - Companies Involved in Therapeutics Development 17
  • Genexine Inc 17
  • Synthonics Inc 17
  • Titan Pharmaceuticals Inc 17
  • Hypothyroidism - Drug Profiles 19
  • (levothyroxine sodium + liothyronine sodium) - Drug Profile 19
  • Product Description 19
  • Mechanism Of Action 19
  • R&D Progress 19
  • BCT-305 - Drug Profile 20
  • Product Description 20
  • Mechanism Of Action 20
  • R&D Progress 20
  • GX-30 - Drug Profile 21
  • Product Description 21
  • Mechanism Of Action 21
  • R&D Progress 21
  • levothyroxine sodium SR - Drug Profile 22
  • Product Description 22
  • Mechanism Of Action 22
  • R&D Progress 22
  • liothyronine - Drug Profile 23
  • Product Description 23
  • Mechanism Of Action 23
  • R&D Progress 23
  • liothyronine sodium SR - Drug Profile 24
  • Product Description 24
  • Mechanism Of Action 24
  • R&D Progress 24
  • liothyronine sodium SR - Drug Profile 25
  • Product Description 25
  • Mechanism Of Action 25
  • R&D Progress 25
  • Hypothyroidism - Dormant Projects 26
  • Hypothyroidism - Product Development Milestones 27
  • Featured News & Press Releases 27
  • Oct 19, 2017: Titan Pharmaceuticals Presents Non-Clinical Data From Liothyronine (L-T3) Implant Studies 27
  • Nov 16, 2015: Titan Pharmaceuticals Adds Proneura Implant For Hypothyroidism To Product Development Pipeline 27
  • Appendix 29
  • Methodology 29
  • Coverage 29
  • Secondary Research 29
  • Primary Research 29
  • Expert Panel Validation 29
  • Contact Us 29
  • Disclaimer 30

List of Tables

  • Number of Products under Development for Hypothyroidism, H2 2017 6
  • Number of Products under Development by Companies, H2 2017 7
  • Products under Development by Companies, H2 2017 8
  • Number of Products by Stage and Target, H2 2017 10
  • Number of Products by Stage and Mechanism of Action, H2 2017 12
  • Number of Products by Stage and Route of Administration, H2 2017 14
  • Number of Products by Stage and Molecule Type, H2 2017 16
  • Hypothyroidism - Pipeline by Genexine Inc, H2 2017 17
  • Hypothyroidism - Pipeline by Synthonics Inc, H2 2017 17
  • Hypothyroidism - Pipeline by Titan Pharmaceuticals Inc, H2 2017 18
  • Hypothyroidism - Dormant Projects, H2 2017 26

List of Figures

  • Number of Products under Development for Hypothyroidism, H2 2017 6
  • Number of Products under Development by Companies, H2 2017 7
  • Number of Products by Targets, H2 2017 9
  • Number of Products by Stage and Targets, H2 2017 9
  • Number of Products by Mechanism of Actions, H2 2017 11
  • Number of Products by Stage and Mechanism of Actions, H2 2017 11
  • Number of Products by Routes of Administration, H2 2017 13
  • Number of Products by Stage and Routes of Administration, H2 2017 13
  • Number of Products by Molecule Types, H2 2017 15
  • Number of Products by Stage and Molecule Types, H2 2017 15
Back to Top